DK stock · Healthcare sector · Biotechnology
G
Genmab A/S
GMAB
NASDAQ37.36
USD
+0.48
(+1.30%)
Market Closed
31.00P/E
3Forward P/E
1.47P/E to S&P500
24.387BMarket CAP
- -Div Yield
Upcoming Earnings
- -
Shares Short
3/15/23
3.09M
Short % of Float
- -
Short % of Shares Outs.
0.47%
% Held by Insiders
- -
% Held by Institutions
7.01%
Beta
0.71
PEG Ratio
0.15
52w. high/low
47.50/26.19
Avg. Daily Volume
0.54M
Return %
Stock
S&P 500
1 year
6.49
(12.11)
3 years
91.46
64.73
5 years
78.00
50.61
Scale: |
High
Low
- -
- -
4.14
1.47
1.78
0.78
1.35
0.65
1.42
0.65
4.67
1.40
6.00
3.39
13.98
5.69
19.41
9.23
23.55
16.21
21.68
12.10
24.50
14.48
41.50
16.24
49.07
30.10
47.50
26.19
43.66
34.65
Currency:
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
1.21
1.67
1.31
1.30
0.78
1.05
1.30
1.51
1.94
3.03
3.89
4.94
8.52
15.51
12.92
22.24
Earnings per share
(0.87)
(2.16)
(2.25)
(0.72)
(1.33)
(1.06)
0.22
0.54
1.30
1.98
1.81
2.40
3.44
7.30
4.58
8.41
FCF per share
1.12
(1.27)
(1.31)
0.57
(0.99)
0.13
(0.27)
0.10
0.30
0.49
2.47
0.88
1.93
9.40
3.01
5.48
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.03
0.12
0.04
0.02
0.02
0.02
0.02
0.13
0.23
0.06
0.15
0.78
0.18
0.47
0.38
0.48
Book Value per sh.
6.56
4.90
2.89
2.41
1.08
0.83
1.29
3.61
5.96
8.06
10.31
13.08
22.31
29.34
33.82
41.81
Comm.Shares outs.
439
446
449
449
449
460
510
563
585
599
608
613
630
652
656
656
Avg. annual P/E ratio
- -
- -
(1.3)
(1.8)
(0.8)
(0.8)
13.7
7.9
6.9
7.8
11.2
7.2
5.5
4.2
8.9
4.2
P/E to S&P500
- -
- -
(0.0)
(0.1)
(0.1)
(0.1)
0.8
0.4
0.3
0.4
0.5
0.3
0.2
0.1
0.3
0.2
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
530
745
586
582
351
485
664
850
1,133
1,816
2,365
3,025
5,366
10,111
8,482
14,595
Operating margin
(82.6)%
(116.8)%
(85.0)%
(27.6)%
(71.1)%
(24.1)%
10.4%
31.2%
64.5%
58.0%
56.8%
45.6%
49.2%
62.4%
35.6%
43.6%
Depreciation (m)
14
85
84
21
15
15
12
12
32
41
70
88
139
259
248
362
Net profit (m)
(383)
(965)
(1,011)
(321)
(596)
(487)
112
301
764
1,187
1,104
1,472
2,166
4,758
3,008
5,522
Income tax rate
- -
(0.1)%
(1.7)%
(17.0)%
(2.8)%
2.3%
(7.3)%
(1.3)%
(0.8)%
(5.0)%
(3.7)%
8.7%
24.2%
19.4%
24.5%
21.5%
Net profit margin
(72.4)%
(129.5)%
(172.5)%
(55.2)%
(169.9)%
(100.5)%
16.9%
35.4%
67.4%
65.4%
46.7%
48.7%
40.4%
47.1%
35.5%
37.8%
Working capital (m)
2,851
905
1,262
1,095
540
470
785
2,110
3,253
4,486
5,732
6,990
13,023
17,538
21,168
26,554
Long-term debt (m)
8
9
18
12
6
2
0
0
- -
- -
- -
- -
155
277
363
523
Equity (m)
2,883
2,189
1,297
1,080
486
383
660
2,033
3,487
4,827
6,272
8,014
14,048
19,121
22,196
27,441
ROIC
(13.2)%
(43.9)%
(75.1)%
(26.4)%
(95.8)%
(93.4)%
14.4%
13.8%
21.9%
24.6%
17.6%
18.4%
15.3%
24.0%
13.1%
19.5%
Return on capital
(9.7)%
(29.6)%
(44.1)%
(10.5)%
(35.0)%
(28.8)%
6.4%
10.5%
19.4%
21.6%
16.2%
19.1%
19.0%
28.0%
16.2%
23.3%
Return on equity
(13.3)%
(44.1)%
(77.9)%
(29.8)%
(122.6)%
(127.1)%
17.0%
14.8%
21.9%
24.6%
17.6%
18.4%
15.4%
24.9%
13.6%
20.1%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
(1,744.2)%
(1.5)%
39.8%
(0.1)%
27.1%
(318.8)%
- -
22.6%
25.3%
Forex (DKK/USD)
0.196
0.188
0.193
0.179
0.174
0.177
0.184
0.163
0.145
0.141
0.161
0.154
0.150
0.164
0.153
0.142
Capital Structure
31 Dec · 2022 | Q4
All numbers in millions
Total liabilities
$ 2,837
Total assets
$ 30,278
Long-term debt
$ 523
Cash and equiv.
$ 9,893
Goodwill
$ - -
Retained earnings
$ 14,968
Common stock
653
Enterprise Value
$ 15,017
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
16,079
19,338
22,324
Receivables
2,712
3,398
6,053
Inventory
- -
- -
- -
Other
- -
1,697
2,633
Current assets
18,791
22,736
28,377
Acc. Payable
- -
- -
- -
Debt due
42
62
74
Other
1,211
1,506
1,749
Current liabilities
1,253
1,568
1,823
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
72.07%
55.44%
44.62%
Cash flow
81.93%
136.12%
113.69%
Earnings
83.58%
53.40%
68.55%
Dividends
- -
- -
- -
Book value
23.63%
37.78%
58.56%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
892
5,451
1,724
2,044
10,111
2021
1,581
1,972
2,310
2,619
8,482
2022
2,119
3,162
4,087
5,227
14,595
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.41
5.18
0.81
0.89
7.30
2021
1.67
0.47
1.36
1.09
4.58
2022
0.71
2.88
3.93
0.89
8.41
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. Jan G.J. van de Winkel Ph.D.
Full-time employees:
1,560
City:
Copenhagen
Address:
Kalvebod Brygge 43
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.